Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

Canadian CRO Innovaderm is looking to expand its operations across the pond with the hiring of Ina Zschocke, Ph.D., as ...

Citizen’s partnership will work with CZI’s Rare As One project, a research and funding network that includes multiple patient ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

An open-label extension study of the phase 3 ATTRibute-CM trial shows that acoramidis produced reductions of 36% and 34% in ...

Incyte’s $750 million Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the ...

A study found that undergoing a cardiac ablation procedure first—before taking any antiarrhythmic therapies—may be the better ...

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...